Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 13/20 | 0.69 |
| ▸ | SCD | O00767 | 6/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536330 | 0.85 | SCD5 (0.69) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21536249 | 0.84 | SCD5 (0.77) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21523775 | 0.81 | SCD5 (1.00) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21523671 | 0.81 | SCD5 (1.00) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21523722 | 0.80 | RAB9A (0.77) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21536311 | 0.79 | SCD5 (0.81) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21523804 | 0.79 | SCD5 (1.00) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21536338 | 0.77 | SCD5 (0.74) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17553956 | 0.77 | NPC1 (1.00) | SCD5SCDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21536435 | 0.76 | SCD5 (0.63) | SCD5SCDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SCD5 1575/4885SCD 2044/4885NPC1 72/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | SCD5 1575/4885SCD 2044/4885NPC1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.